BMY - Bristol-Myers Squibb Company
NYSE
->
Healthcare
->
Drug Manufacturers—General
New York,
United States
Type: Equity
BMY price evolution
BMY
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11464 | $7514 | $8372 | $8995 |
| Short term investments | $816 | $171 | $358 | $274 |
| Net receivables | $10921 | $10304 | $10112 | $10054 |
| Inventory | $2662 | $2436 | $2364 | $2605 |
| Total current assets | $31770 | $27632 | $28074 | $27086 |
| Long term investments | $364 | $325 | ||
| Property, plant & equipment | $6646 | $6481 | $6355 | $6279 |
| Goodwill & intangible assets | $48241 | $50097 | $52466 | $54731 |
| Total noncurrent assets | $63389 | $63631 | $65415 | $67195 |
| Total investments | $1180 | $496 | $358 | $274 |
| Total assets | $95159 | $91263 | $93489 | $94281 |
| Current liabilities | ||||
| Accounts payable | $3259 | $2813 | $3069 | $3194 |
| Deferred revenue | ||||
| Short long term debt | $3119 | $5467 | $3020 | $2752 |
| Total current liabilities | $22262 | $23462 | $20150 | $19085 |
| Long term debt | $36653 | $32137 | $34656 | $35078 |
| Total noncurrent liabilities | $43412 | $38739 | $41309 | $43310 |
| Total debt | $39772 | $37604 | $37676 | $37830 |
| Total liabilities | $65674 | $62201 | $61459 | $62395 |
| Shareholders' equity | ||||
| Retained earnings | $28766 | $28218 | $27449 | $26568 |
| Other shareholder equity | -$1546 | -$1286 | -$1387 | -$1368 |
| Total shareholder equity | $29430 | $28998 | $31973 | $31824 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11464 | $9123 | $13979 | $14546 |
| Short term investments | $816 | $130 | $2987 | $1285 |
| Net receivables | $10921 | $9886 | $9369 | $8501 |
| Inventory | $2662 | $2339 | $2095 | $2074 |
| Total current assets | $31770 | $27273 | $33262 | $30192 |
| Long term investments | $364 | $433 | ||
| Property, plant & equipment | $6646 | $7475 | $6049 | $5886 |
| Goodwill & intangible assets | $48241 | $57008 | $63029 | $73790 |
| Total noncurrent assets | $63389 | $69547 | $76052 | $88289 |
| Total investments | $1180 | $130 | $2987 | $1718 |
| Total assets | $95159 | $96820 | $109314 | $118481 |
| Current liabilities | ||||
| Accounts payable | $3259 | $3040 | $2949 | $2713 |
| Deferred revenue | ||||
| Short long term debt | $3119 | $4264 | $4948 | $2340 |
| Total current liabilities | $22262 | $21890 | $21868 | $19080 |
| Long term debt | $36653 | $35056 | $39605 | $48336 |
| Total noncurrent liabilities | $43412 | $43812 | $51440 | $61519 |
| Total debt | $39772 | $39320 | $44553 | $50676 |
| Total liabilities | $65674 | $65759 | $73308 | $80599 |
| Shareholders' equity | ||||
| Retained earnings | $28766 | $25503 | $23820 | $21281 |
| Other shareholder equity | -$1546 | -$1281 | -$1268 | -$1839 |
| Total shareholder equity | $29430 | $31061 | $35946 | $37822 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11477 | $10966 | $11226 | $11337 |
| Cost of revenue | $2506 | $2876 | $2566 | |
| Gross Profit | $8770 | $8460 | $8350 | $8771 |
| Operating activities | ||||
| Research & development | $2242 | $2258 | $2321 | |
| Selling, general & administrative | $2003 | $1934 | $1762 | |
| Total operating expenses | $6159 | $6323 | $6491 | $6001 |
| Operating income | $2137 | $1859 | $2770 | |
| Income from continuing operations | ||||
| EBIT | $2131 | $1855 | $2765 | |
| Income tax expense | -$88 | $203 | -$218 | $503 |
| Interest expense | -$118 | |||
| Net income | ||||
| Net income | $1762 | $1928 | $2073 | $2262 |
| Income (for common shares) | $1928 | $2073 | $2262 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $45006 | $46159 | $46385 | $42518 |
| Cost of revenue | $10137 | $9940 | $11773 | |
| Gross Profit | $34488 | $36022 | $36445 | $30745 |
| Operating activities | ||||
| Research & development | $9509 | $11354 | $11143 | |
| Selling, general & administrative | $7814 | $7690 | $7661 | |
| Total operating expenses | $23582 | $28309 | $28347 | $37616 |
| Operating income | $7713 | $8098 | -$6871 | |
| Income from continuing operations | ||||
| EBIT | $7695 | $8078 | -$6891 | |
| Income tax expense | $400 | $1368 | $1084 | $2124 |
| Interest expense | -$877 | |||
| Net income | ||||
| Net income | $8025 | $6327 | $6994 | -$9015 |
| Income (for common shares) | $6327 | $6994 | -$9015 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $1762 | $1928 | $2073 | $2262 |
| Operating activities | ||||
| Depreciation | $2464 | $2435 | $2432 | $2429 |
| Business acquisitions & disposals | -$340 | -$79 | $10 | $149 |
| Stock-based compensation | $127 | $132 | $137 | $122 |
| Total cash flows from operations | $4252 | $4751 | $1887 | $2970 |
| Investing activities | ||||
| Capital expenditures | -$330 | -$342 | -$259 | -$278 |
| Investments | -$676 | $11 | -$80 | -$81 |
| Total cash flows from investing | -$1346 | -$410 | -$329 | -$210 |
| Financing activities | ||||
| Dividends paid | -$1160 | -$1191 | -$1197 | -$1196 |
| Sale and purchase of stock | $25 | -$3959 | -$852 | -$250 |
| Net borrowings | $2102 | -$10 | -$124 | -$1512 |
| Total cash flows from financing | $967 | -$5160 | -$2173 | -$3050 |
| Effect of exchange rate | $78 | -$38 | -$8 | $13 |
| Change in cash and equivalents | $3951 | -$857 | -$623 | -$277 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $8025 | $6327 | $6994 | -$9015 |
| Operating activities | ||||
| Depreciation | $9760 | $10276 | $10686 | $10380 |
| Business acquisitions & disposals | -$260 | -$2981 | -$862 | -$12214 |
| Stock-based compensation | $518 | $457 | $583 | $779 |
| Total cash flows from operations | $13860 | $13066 | $16207 | $14052 |
| Investing activities | ||||
| Capital expenditures | -$1209 | -$1118 | -$973 | -$753 |
| Investments | -$826 | $3037 | $1297 | $2108 |
| Total cash flows from investing | -$2295 | -$1062 | -$538 | -$10859 |
| Financing activities | ||||
| Dividends paid | -$4744 | -$4634 | -$4396 | -$4075 |
| Sale and purchase of stock | -$5128 | -$8001 | -$6287 | -$1546 |
| Net borrowings | $456 | -$5311 | -$6182 | $3928 |
| Total cash flows from financing | -$9416 | -$16962 | -$16224 | -$1151 |
| Effect of exchange rate | $45 | -$33 | -$102 | $111 |
| Change in cash and equivalents | $2194 | -$4991 | -$657 | $2153 |
News
Fundamentals
| Market cap | $96.68B |
|---|---|
| Enterprise value | $124.99B |
| Shares outstanding | 2.02B |
| Revenue | $45.01B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $8.03B |
| Revenue Q/Q | 0.62% |
| Revenue Y/Y | -2.50% |
| P/E ratio | 12.05 |
|---|---|
| EV/Sales | 2.78 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.15 |
| P/B ratio | 3.12 |
| Book/Share | 15.33 |
| Cash/Share | 5.67 |
| EPS | $3.97 |
|---|---|
| ROA | 8.58% |
| ROE | 26.26% |
| Debt/Equity | 2.23 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.43 |
| Quick ratio | 1.31 |